PEPTIDE PERFORMANCE RESEARCH LIBRARY
An educational overview of the investigational triple-receptor agonist studied for its effects on metabolic signaling, energy regulation, and body-weight regulation.
RESEARCH OVERVIEW
RECEPTOR ACTIVITY
GL3R is being investigated as an agonist of three metabolic hormone receptor systems: GIP, GLP-1, and glucagon receptors. Researchers are studying how simultaneous activity across these pathways may influence metabolic regulation.
METABOLIC RESEARCH
Clinical research has examined changes in body weight, appetite-related signaling, glucose regulation, substrate utilization, and other metabolic outcomes associated with triple-receptor agonism.
CLINICAL DEVELOPMENT
GL3R has been evaluated in randomized clinical studies, including Phase 2 and Phase 3 research involving adults with obesity or overweight and related metabolic conditions.
MECHANISMS UNDER INVESTIGATION
The scientific interest surrounding GL3R centers on the combination of three receptor pathways involved in nutrient sensing, appetite regulation, glucose metabolism, and energy balance.
GIP signaling is involved in nutrient-responsive endocrine activity and insulin-related metabolic pathways.
GLP-1 receptor signaling has established roles in appetite, glucose-dependent insulin secretion, gastric function, and metabolic regulation.
Glucagon receptor activity is being investigated for its potential contribution to hepatic metabolism, substrate utilization, and energy expenditure.
PUBLISHED EVIDENCE
PHASE 2
A randomized Phase 2 trial involving 338 adults evaluated the compound over 48 weeks. Researchers reported dose-dependent reductions in body weight, with the highest-dose group showing a mean reduction of approximately 24% at week 48.
PHASE 3
The clinical development program has progressed into Phase 3 studies examining obesity, overweight, metabolic disease, and associated health conditions across larger participant populations.
IMPORTANT CONTEXT
Despite advanced clinical research, GL3R remains an investigational compound. Ongoing research continues to evaluate long-term efficacy, safety, tolerability, and clinical outcomes.
RESEARCH LIMITATIONS
Strong early and late-stage clinical findings do not eliminate unanswered questions. Long-term safety, durability of outcomes, population-specific effects, and the complete risk-benefit profile require continued investigation.
RESEARCH SOURCES
Phase 2 Obesity Trial
Jastreboff AM, Kaplan LM, Frías JP, et al.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity —
A Phase 2 Trial. New England Journal of Medicine.
2023;389:514-526.
Phase 3 Clinical Development
TRIUMPH clinical research program evaluating the
investigational GIP, GLP-1, and glucagon receptor agonist
in obesity, overweight, and related metabolic conditions.
EDUCATIONAL RESEARCH NOTICE
Information presented in the Peptide Performance Research Library is provided for general educational and scientific reference purposes only.
This content is not medical advice, diagnosis, treatment guidance, or personal-use instruction. Research findings may change as additional clinical evidence becomes available.
